MedTrace Logo

Comparative Study of Anaconda System Use Versus Conventional Sedation in COVID-19 Patients.

NCT06208592 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2024-01-26

No results posted yet for this study

Summary

At the beginning of 2020, a global alert emerged which saturated intensive care units due to COVID-19 worldwide. This caused a need for mechanical ventilation due to atypical pneumonias that had a rapid evolution and respiratory failure; therefore the consumption of sedative agents in the intensive care units escalated. Suboptimal sedation in the intensive care unit, increases the adverse effects, costs, and morbidity. For the time being, they focus on the use of intravenous agents such as propofol or dexmedetomidine, which are associated with tolerance, withdrawal, delirium, and hemodynamic effects. Consequently, the need arises to maximize availability and effectiveness, which is why the intervention of the ANACONDA conservation device is carried out, which works with a heat and humidity exchange filter capable of administering isoflurane or sevoflurane with an efficiency of 90%.

Conditions

Interventions

DEVICE

Sevoflurane with AnaConDa

Sevoflurane administered with AnaConDa device

Sponsors & Collaborators

  • Universidad Nacional Autonoma de Mexico

    collaborator OTHER

  • Hospital Español de Mexico

    lead OTHER

Principal Investigators

  • Manuel Lomeli, MD · Hospital H+ Queretaro

Eligibility

Min Age
27 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-30
Primary Completion
2020-09-18
Completion
2020-11-06

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06208592 on ClinicalTrials.gov